BUCHANG PHARMA(603858)2023-10-27 16:00Revenue and Profit Performance - Revenue for the third quarter of 2023 was RMB 3,025,545,041.21, a decrease of 28.08% compared to the same period last year[4] - The company's revenue for the first nine months of 2023 was RMB 9,983,222,406.98, a decrease of 11.69% compared to the same period last year[4] - Total revenue for the first three quarters of 2023 was RMB 9.983 billion, a decrease of 11.7% compared to RMB 11.305 billion in the same period last year[15] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 179,005,384.96, a decrease of 60.09% year-on-year[4] - Net profit attributable to the parent company's shareholders was RMB 925.14 million, a decrease of 27% compared to RMB 1.267 billion in the same period last year[15] - Basic earnings per share for the third quarter were RMB 0.1618, a decrease of 60.09% year-on-year[4] - Basic earnings per share for the first three quarters of 2023 were RMB 0.8364, a decrease of 27% compared to RMB 1.1454 in the same period last year[16] Assets and Liabilities - The company's total assets as of the end of the reporting period were RMB 20,618,947,644.56, a decrease of 6.07% compared to the end of the previous year[5] - Total assets as of September 30, 2023, were RMB 20.619 billion, a decrease of 6.1% compared to RMB 21.952 billion at the end of 2022[14] - Total liabilities as of September 30, 2023, were RMB 8.557 billion, a decrease of 11.6% compared to RMB 9.677 billion at the end of 2022[14] - Total equity attributable to the parent company's shareholders was RMB 12.225 billion as of September 30, 2023, a decrease of 1.1% compared to RMB 12.363 billion at the end of 2022[14] Cash Flow and Liquidity - Operating cash flow for the period from the beginning of the year to the end of the reporting period was negative RMB 411,801,039.75, a decrease of 118.08% compared to the same period last year[4] - The company's cash and cash equivalents decreased by 74% to RMB 558.84 million as of September 30, 2023, compared to RMB 2.149 billion at the end of 2022[13] - Sales revenue from goods and services received in cash for the first three quarters of 2023 was 10,091,889,612.09, a decrease from 11,649,730,730.24 in the same period of 2022[17] - Net cash flow from operating activities for the first three quarters of 2023 was -411,801,039.75, compared to 2,278,196,609.29 in the same period of 2022[17] - Net cash flow from investing activities for the first three quarters of 2023 was -40,298,345.35, an improvement from -1,105,471,325.13 in the same period of 2022[17] - Net cash flow from financing activities for the first three quarters of 2023 was -1,195,419,556.37, compared to -861,346,685.73 in the same period of 2022[17] - The net increase in cash and cash equivalents for the first three quarters of 2023 was -1,647,500,652.20, a significant decline from 311,552,379.85 in the same period of 2022[18] - The ending balance of cash and cash equivalents as of September 2023 was 473,815,895.66, down from 1,674,826,286.57 in September 2022[18] Shareholder and Equity Information - The company's largest shareholder, Step (Hong Kong) Holdings Limited, holds 44.39% of the shares[9] - The number of ordinary shareholders at the end of the reporting period was 73,221[9] - The weighted average return on equity (ROE) for the reporting period was 1.48%, a decrease of 1.07 percentage points compared to the same period last year[5] Expenses and Inventory - R&D expenses decreased by 36% to RMB 151.01 million in the first three quarters of 2023, compared to RMB 235.71 million in the same period last year[15] - Sales expenses decreased by 11.6% to RMB 4.840 billion in the first three quarters of 2023, compared to RMB 5.478 billion in the same period last year[15] - Inventory increased by 22.7% to RMB 4.651 billion as of September 30, 2023, compared to RMB 3.789 billion at the end of 2022[13] Government Subsidies - Government subsidies received during the reporting period amounted to RMB 10,531,737.30[6]